Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe

J. E. Swartz, L. Vandekerckhove, H. Ammerlaan, A. C. de Vries, J. Begovac, W. F. W. Bierman, C. A. B. Boucher, M. E. van der Ende, Z. Grossman, R. Kaiser, I. Levy, T. Mudrikova, R. Paredes, D. Perez-Bercoff, M. Pronk, C. Richter, J. C. Schmit, J. Vercauteren, M. Zazzi, S. Zidovec LepejA. De Luca, A. M. J. Wensing*, European Soc Translational

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    9 Citations (Scopus)

    Abstract

    Background: The combination of tenofovir and efavirenz with either lamivudine or emtricitabine (TELE) has proved to be highly effective in clinical trials for first-line treatment of HIV-1 infection. However, limited data are available on its efficacy in routine clinical practice.

    Methods: A multicentre cohort study was performed in therapy-naive patients initiating ART with TELE before July 2009. Efficacy was studied using ITT (missing or switch = failure) and on-treatment (OT) analyses. Genotypic susceptibility scores (GSSs) were determined using the Stanford HIVdb algorithm.

    Results: Efficacy analysis of 1608 patients showed virological suppression to

    Conclusions: In clinical practice, treatment failure on TELE regimens is relatively frequent due to toxicity. Virological failure is rare and more often observed with lamivudine than with emtricitabine. Following virological failure on TELE, PI-based second-line therapy was often successful despite GSS

    Original languageEnglish
    Pages (from-to)1850-1857
    Number of pages8
    JournalJournal of Antimicrobial Chemotherapy
    Volume70
    Issue number6
    DOIs
    Publication statusPublished - Jun-2015

    Keywords

    • HIV-1
    • first-line antiretroviral therapy
    • co-formulation
    • SINGLE-TABLET REGIMEN
    • EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
    • REVERSE-TRANSCRIPTASE INHIBITORS
    • VIROLOGICAL FAILURE
    • HIV-1 INFECTION
    • RESISTANCE PROFILES
    • HAART COMBINATIONS
    • CONTROLLED-TRIAL
    • NON-INFERIORITY
    • THERAPY

    Cite this